Rheumatoid vasculitis occurring alongside seropositive rheumatoid arthritis, coded without specification of which joint site is involved.
Verified May 8, 2026 · 6 sources ↓
- Status
- Billable
- Chapter
- 13
- Related CPT
- 10
- Region
- General
Documentation tips
What should appear in the chart to support M05.20.
Source · Editorial brief grounded in 6 cited references ↓
- Record the serostatus explicitly — note rheumatoid factor (RF) titer or anti-CCP result to justify M05 over M06.
- Name the specific joint site involved in the vasculitic process whenever possible to move off the unspecified M05.20 to a site-specific code (e.g., M05.261 for right knee).
- Document cutaneous, neurological, or visceral manifestations of vasculitis (e.g., skin ulcers, digital ischemia, mononeuritis multiplex) as separate diagnoses to support MCC/CC assignment.
- Record the date and result of the most recent RF and anti-CCP labs; PMC research shows agreement between M05 coding and seropositivity improves when labs precede the coding encounter by more than six months.
- Note any DMARDs, biologics, or glucocorticoids in use — these support medical necessity for rheumatology management visits and biologic infusion claims.
Related CPT procedures
Procedure codes commonly billed with M05.20. Linking the right diagnosis to the right procedure is what establishes medical necessity.
Source · CMS LCDs · AAOS specialty guidance · claims-pattern analysis
Common coding pitfalls
The recurring mistakes coders make with M05.20 and adjacent codes.
Source · Editorial brief grounded in CDC ICD-10-CM tabular guidance, AAOS coding references, and cited references ↓
- Defaulting to M05.20 when the joint site is actually documented — always check the note for laterality and site before landing on unspecified.
- Using M05.20 for seronegative RA patients: M05 codes require seropositive status; seronegative RA with vasculitis belongs under M06.
- Confusing rheumatoid vasculitis (M05.2x) with other systemic vasculitides (e.g., ANCA-associated vasculitis) — M05.2x is exclusive to RA-related vascular inflammation.
- Failing to code the vasculitic manifestations (e.g., skin ulcers, neuropathy) as additional diagnoses, which can suppress CC/MCC capture and lower the DRG tier.
- Assigning M05.20 based solely on EHR auto-suggested codes without verifying that the provider's documentation explicitly supports both the vasculitis and the RA diagnosis.
Clinical context
Source · Editorial summary grounded in 6 cited references ↓
M05.20 is the fallback code within the M05.2x subcategory when documentation confirms rheumatoid vasculitis with seropositive rheumatoid arthritis but fails to identify a specific joint site. Rheumatoid vasculitis is a systemic, inflammatory blood vessel complication of RA — distinct from the arthritis itself — characterized by skin ulceration, digital infarcts, peripheral neuropathy, and organ involvement. The M05 category signals seropositive RA (rheumatoid factor–positive and/or anti-CCP positive); if seronegativity is documented, M06 codes apply instead.
Use M05.20 only when no site is documented or determinable. If the affected joint is documented, site-specific codes exist for every major joint (shoulder M05.21x, elbow M05.22x, wrist M05.23x, hand M05.24x, hip M05.25x, knee M05.26x, ankle/foot M05.27x, and M05.29 for multiple sites). The unspecified code M05.20 should not be a default — it should reflect a genuine documentation gap that couldn't be clarified.
For DRG assignment, M05.20 maps to MS-DRG v43.0 groups 545 (connective tissue disorders with MCC), 546 (with CC), and 547 (without CC/MCC). Because rheumatoid vasculitis is a serious systemic complication that can qualify as an MCC depending on the payer, accurate capture of comorbidities in the encounter record directly affects reimbursement tier.
Sibling codes
Other billable codes under M05.2 (laterality / anatomic variants).
Frequently asked questions
Source · Generated from the editorial pipeline, verified against 6 cited references ↓
01When is M05.20 appropriate versus a site-specific M05.2x code?
02Does M05.20 require the patient to be RF-positive?
03Can M05.20 be a primary diagnosis, or must RA be listed first?
04What DRGs does M05.20 map to?
05Is there an Excludes1 or Excludes2 note that affects M05.20?
06How does M05.20 affect HCC risk adjustment?
07Should I code vasculitic skin manifestations separately when using M05.20?
Sources & references
Editorial content was developed using the following public sources. Last verified May 8, 2026.
- 01CDC ICD-10-CM Tabular List 2026 (FY2026, effective Oct 1 2025)
- 02icd10data.comhttps://www.icd10data.com/ICD10CM/Codes/M00-M99/M05-M14/M05-/M05.20
- 03pmc.ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC7560310/
- 04aapc.comhttps://www.aapc.com/codes/icd-10-codes/M05.20
- 05rhinomds.comhttps://rhinomds.com/m05-icd-10-codes-for-rheumatoid-arthritis-2026-a-billing-coding-guide/
- 06uptodate.cnhttps://www.uptodate.cn/contents/treatment-of-rheumatoid-vasculitis
Mira AI Scribe
Mira's AI scribe captures serostatus (RF titer, anti-CCP result), the specific joint or vascular territory involved, active vasculitic manifestations (skin ulcers, digital infarcts, neuropathy), and current biologic or DMARD therapy from the encounter note. That documentation prevents defaulting to the unspecified M05.20 when a site-specific M05.2x code is supportable, and it surfaces comorbidities that drive CC/MCC assignment in the connective tissue DRG grouping.
See how Mira captures M05.20 documentation